Jeffrey Glenn, M.D., Ph.D. is a Professor of Medicine (Division of Gastroenterology & Hepatology) and Microbiology & Immunology at Stanford University School of Medicine, and the Director of the Center for Hepatitis and Liver Tissue Engineering. He also heads a research laboratory focused on studying molecular virology and the translation of that knowledge into novel antiviral strategies, as well as the development of new treatments for liver diseases and cancer. He leads ViRx@Stanford, which seeks to increase our collective antiviral tool kit to counter pandemics in a proactive, rather than reactive, fashion. He is the founder of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), co-founder of Riboscience LLC, and founder of I-Cubed Therapeutics, biotechnology companies developing several new classes of antiviral and anti-cancer drugs.

Glenn was born in Los Angeles, and grew up in Switzerland. He received his B.A. degree in Biochemistry and French Civilization from U.C. Berkeley from where he graduated summa cum laude. He received his M.D. and Ph.D. in Biochemistry and Biophysics from U.C.S.F.. He trained in internal medicine at Stanford University where he completed specialty training in gastroenterology, and joined the faculty in 2000.

He is the principal investigator on multiple NIH grants, an inventor on numerous patents, an elected member of the American Society for Clinical Investigation, and a member of the FDA Antiviral Drugs Advisory Committee.

Dr. Edward Pham is the deputy director for translational research of ViRx@Stanford and codirects ViRx@Stanford-Vietnam. He is a physician-scientist at the Stanford University School of Medicine, an instructor in medicine in the division of gastroenterology and hepatology. His research focus is on novel antiviral therapies for current and emerging viral infections, the relationship between chronic viral infection, inflammation, and cancer through studying how the innate and adaptive immune system are perturbed in chronic viral infection, which can form the basis for new anti-cancer therapeutics as well as therapeutics to combat fatty-liver associated diseases and other inflammatory disorders.

He grew up in Vietnam, completed his undergraduate in Bioengineering at UCLA where he graduated summa cum laude and elected to both Phi Beta Kappa and Tau Beta Pi. He received his M.D and Ph.D in Microbiology & Immunology from Stanford University. He has been recognized by many prestigious awards such as the Soros Fellowship for New Americans, Gates Millennium Scholar, Howard Hughes Medical Institute, and an International Achievement Summit Delegate.

Dr. Mark Smith joined Stanford ChEM-H in May 2013 as the Head of the Medicinal Chemistry Knowledge Center. He graduated with a Ph.D. from the laboratory of Prof. Richard Stoodley at the University of Manchester Institute for Science and Technology (UMIST), where his research focused on the application of Lewis acid catalyzed hetero Diels-Alder reactions to the synthesis of novel disaccharide structures. In 2000, Dr.

Smith joined the research laboratory of Prof. David Crich at the University of Illinois at Chicago. Here his research focused on the generation of new reagents for the synthesis of beta-mannosides from thioglycosides. From 2002 to 2013, Dr. Smith worked as a medicinal chemist in Roche’s research facilities both in Palo Alto, CA and then Nutley, NJ, where he specialized in antiviral research.

Wendy is the CEO of IMI.AI, a company that allow doctors to give medical advice to patients seamlessly. Wendy has a proven executive management track record with almost ten years of experience in the healthcare and business industry. Wendy was previously Co-founder/CEO of Med2lab, a startup focuses on innovating medical training. The system got adopted by Stanford School of Medicine.

Before that, she spent 5 years in the Management Team at Marin General Hospital, working closely with the CEO, Lee Domanico, as her mentor. Wendy also acts as the President and Founder of Apollo Care, a 501(c)3 nonprofit organization that provides free healthcare support to poor children oversea. She’s also an alumni of Y Combinator founder track, one of the top incubators in the world.

Wendy attended Graduate program from the University of California, San Francisco and a Bachelor Degree in Psychology from UMass Amherst.

Ms. Shekou has over 20 years of experience in real estate acquisitions and dispositions, commercial leasing, joint venture formations and commercial finance. She’s a major philanthropist and a Board Member of Marin Foundation and Marin Symphony.

Ms. Shekou is a member of American Bar Association and recognized numerous times as Super Lawyer in Northern California. She graduated with Highest Honors from University of California, Berkeley law and member of Phi Beta Kapa Honor Society.

Lee Domanico has led hospitals and health systems across the country. He is known for his ability to transform underperforming organizations into those of high achievement. Lee served as the Chief Executive Officer of MarinHealth, in Marin County, CA, where he led the transfer of the hospital from a large system to a successful free-standing publicly accountable hospital. He secured financing and built the operating and governance organization that currently oversees MarinHealth Medical Center (MHMC), starting with only 7 days of cash on hand. Recently the hospital raised $400M in public funding; $65M in philanthropy and $100M in debt to rebuild the hospital. Secured $340M in new funding through strategic alliance with major academic health system. Under his leadership, MHMC has received numerous awards for quality and safety and is ranked in the top 5% nationally for safety and clinical outcomes. Implemented full telehealth/technology program in response to COVID-19 Pandemic.

Prior to MarinHealth, Lee led El Camino Hospital in Mountain View, California. Under his leadership, El Camino Hospital became one of the most profitable district hospitals in the State and developed superlative medical programs. Prior to joining El Camino Hospital, Domanico led the re-emergence of the Allegheny Health System in Philadelphia from bankruptcy to healthy profits, where he received the “Philadelphia Business Leader of the Year” award.

Domanico previously held executive leadership positions as CEO at the Columbus-Cabrini Health System in Chicago, IL, as V.P in Los Angeles, CA, and as Sr. V.P. of Pennsylvania with Tenet Healthcare, and as CEO of Legacy Health System in Portland, Oregon.

Domanico is known for establishing healing, patient-centric hospital environments and for early adoption of cutting-edge medical technologies. He has 30+ years of experience as a Hospital and Health System CEO.

Domanico holds a BS degree (Magna Cum Laude) in Industrial Engineering from the University of Michigan and an MS degree in Industrial Engineering from Stanford.

He then joined the laboratory of Professor Jeffrey Glenn's at Stanford School of Medicine as a postdoctoral fellow in 2000 then became a senior research scientist. He initially focused his research on how RNA viruses harness cellular membrane to support their genome’s replication. In recent years, his research expanded to include broad spectrum antivirals targeting host function; viral genome RNA structures as antiviral targets; and other direct-targeting antivirals

Dr. Edward Mills is a Professor at McMaster University in the Department of Health Research Methods, Impact, and Evaluation. He is also the Chief Scientist at Platform Life Sciences and the Principal Investigator of the TOGETHER adaptive platform trial for the evaluation of COVID-19 therapeutics. He additionally leads the clinical trial services for the Bill & Melinda Gates Foundation.

Dr. Mills has published over 550 peer reviewed papers, including several papers in high impact medical journals such as New England Journal of Medicine, The Lancet, JAMA, and BMJ. He has been the principal investigator of several large-scale clinical trials and cohort studies, particularly in HIV. He has also authored several clinical guidelines on systematic reviews and network analysis supporting national and global HIV guidelines. He also led the first ever network meta-analysis to inform WHO global guidelines and has since been instrumental in promoting the use of network meta-analysis for global clinical guidelines.

Dr. Gilmar Reis is an associate professor of medicine at the Pontifical Catholic University of Minais Gerais, located in Belo Horizonte, Brazil and also an associate professor of medicine at McMaster Universiry, Hamilton, Canada. He is the co-Principal Investigator of the TOGETHER. He is also the Founder and Executive Director of CardResearch, an academic research organization with a more than a decade of experience in implementing clinical trials in Brazil, running more than 50 trials for projects involving cardiovascular health and treatments. Dr. Reis is also a practicing cardiologist and has extensively published clinical findings in the field of medicine, with more than 150 publications, and he has been on the board of the Brazilian Cardiology Society, the Brazilian Cardiology Journal and the Minas Gerais Cardiology Scoiety. Currently, he is leading and managing a growing research network with more than 22 research sites in Minas Gerais State, Brazil as part of the TOGETHER Trial, and coordinating with partners in Sao Francisco Hospital Complex, Belo Horizonte, Brazil.